<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006907" GROUP_ID="PREG" ID="643606111417432947" MERGED_FROM="" MODIFIED="2011-06-10 15:43:29 +0200" MODIFIED_BY="Frances Kellie" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-06-10 10:40:50 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0560" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2011-06-10 15:43:29 +0200" MODIFIED_BY="Frances Kellie">
<TITLE MODIFIED="2011-03-30 16:30:26 +0100" MODIFIED_BY="[Empty name]">Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension</TITLE>
<CONTACT MODIFIED="2011-06-10 15:43:29 +0200" MODIFIED_BY="Frances Kellie"><PERSON ID="5E13113D82E26AA20178986B1BF20BE3" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ashraf</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Nabhan</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>ashraf.nabhan@gmail.com</EMAIL_1><EMAIL_2>anabhan@med.asu.edu.eg</EMAIL_2><MOBILE_PHONE>+20 123317347</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>Ain Shams University</ORGANISATION><ADDRESS_1>16 Ali Fahmi Kamel Street</ADDRESS_1><ADDRESS_2>Heliopolis</ADDRESS_2><CITY>Cairo</CITY><ZIP>11351</ZIP><COUNTRY CODE="EG">Egypt</COUNTRY><PHONE_1>+20 2263 57966</PHONE_1><PHONE_2>+20 2264 47500</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-06-10 15:43:29 +0200" MODIFIED_BY="Frances Kellie"><PERSON ID="5E13113D82E26AA20178986B1BF20BE3" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ashraf</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Nabhan</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>ashraf.nabhan@gmail.com</EMAIL_1><EMAIL_2>anabhan@med.asu.edu.eg</EMAIL_2><MOBILE_PHONE>+20 123317347</MOBILE_PHONE><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>Ain Shams University</ORGANISATION><ADDRESS_1>16 Ali Fahmi Kamel Street</ADDRESS_1><ADDRESS_2>Heliopolis</ADDRESS_2><CITY>Cairo</CITY><ZIP>11351</ZIP><COUNTRY CODE="EG">Egypt</COUNTRY><PHONE_1>+20 2263 57966</PHONE_1><PHONE_2>+20 2264 47500</PHONE_2></ADDRESS></PERSON><PERSON ID="D1D597B882E26AA2005274A3832A82C7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maged</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Elsedawy</LAST_NAME><POSITION>Resident doctor</POSITION><EMAIL_1>maged.sedawy@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>El-Sahel Teaching Hospital</ORGANISATION><ADDRESS_1>5 - Abd El Gawad Salem Street</ADDRESS_1><CITY>Cairo</CITY><ZIP>11762</ZIP><REGION>Nasr City</REGION><COUNTRY CODE="EG">Egypt</COUNTRY><PHONE_1>+20 2267 13871</PHONE_1><FAX_1>+20 1056 47494</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-05-12 11:25:06 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="12" MONTH="5" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="3" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="4" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2009-03-25 11:42:26 +0000" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2009-03-25 11:43:19 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-03-25 11:42:26 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-03-12 11:56:13 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-06-10 10:38:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-06-10 00:14:08 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-03-30 16:38:48 +0100" MODIFIED_BY="[Empty name]">Tight control of mild-to-moderate high blood pressure for pregnant women with pre-existing or gestational hypertension (without protein in the urine) to improve health outcomes </TITLE>
<SUMMARY_BODY MODIFIED="2011-06-10 00:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>High blood pressure (hypertension) is defined as a systolic blood pressure of 140 mmHg or more or a diastolic blood pressure of 90 mmHg or more. In the general population, a tight control of blood pressure reduces cardiovascular risks and is particularly important for people with diabetes or renal disease. Having high blood pressure during pregnancy is a complex clinical condition. Adverse effects include premature separation of the placenta (abruption), low birthweight, and perinatal death. Women who do not have regular antenatal care, those with severe uncontrolled hypertension and pre-eclampsia are more likely to have poor outcomes. A woman with mild-to-moderate hypertension could develop severe hypertension if not managed correctly. On the other hand, lowering blood pressure dramatically may reduce placental perfusion, which could lead to fetal growth restriction, without providing extra benefit to the mother. There is no consensus regarding a clear goal of adjusting blood pressure in pregnant women with mild-to-moderate hypertension.</P>
<P>This systematic review set out to compare the effects of 'tight' versus 'very tight' control of mild to moderate pre-existing or non-proteinuric gestational hypertension on pregnancy outcomes. It found insufficient evidence to determine which degree of control of blood pressure during pregnancy was more effective for improving outcomes for the mother and her baby. The review included two trials that studied 256 women. A blood pressure target of less than 130/80 mm Hg using methyldopa reduced the rate of admission to hospital during pregnancy. There was no evidence of a difference between tight and very tight control groups regarding severe pre-eclampsia, induction of labor and cesarean delivery and no cases of eclampsia or maternal deaths.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-06-10 09:04:11 +0100" MODIFIED_BY="Denise Atherton">
<ABS_BACKGROUND MODIFIED="2009-02-04 16:00:54 +0000" MODIFIED_BY="[Empty name]">
<P>The question of the target blood pressure in pregnant women with mild-moderate hypertension continues to be an area of debate. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-07-18 15:26:28 +0100" MODIFIED_BY="[Empty name]">
<P>To compare tight versus very tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension for improving outcomes</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-04-15 11:46:43 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 March 2011), CENTRAL (<I>The Cochrane Library</I> 2011, Issue 3), MEDLINE (January 1966 to March 2011), and the metaRegister of Controlled Trials (31 March 2011). We handsearched citation lists of relevant publications, review articles, and included studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-02-04 16:03:34 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials of tight versus very tight control in pregnant women with mild or moderate pre-existing or non-proteinuric gestational hypertension. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-06-09 23:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently assessed trial quality and extracted data. We expressed results as risk ratio (RR) or mean differences, together with their 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-06-10 09:04:11 +0100" MODIFIED_BY="Denise Atherton">
<P>We included two studies (256 participants) with mild-moderate pre-existing or non-proteinuric gestational hypertension. There was no evidence of a difference between tight and very tight control groups regarding severe pre-eclampsia (risk ratio (RR) 1.28, 95% CI 0.97 to 1.70; two trials, 256 participants). More women in the tight group were hospitalized during their pregnancy (RR 2.53, 95% CI 1.14 to 5.63; one trial, 125 participants). There was no evidence of a difference in other outcome measures including fetal distress, IUGR, neonatal admission to a NICU, perinatal deaths, induction of labor and cesarean delivery between the tight and the very tight control groups. Gestational age at delivery had a non-significant mean difference (MD) of -0.15 weeks between the tight and very tight control groups (MD -0.15, 95% CI -1.52 to 1.21, random-effects, T² = 0.75, I² = 77%; two trials, 256 participants). The MD in birthweight between the tight and the very tight control group was not significant (MD -100.00 grams, 95% CI -363.69 to 163.69; one trial, 125 participants).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-03-30 16:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>For pregnant women with non-severe pre-existing or non-proteinuric gestational hypertension, there is insufficient evidence to determine how tight control of hypertension should be achieved to improve maternal and fetal-neonatal outcomes.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-06-10 10:38:26 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-06-10 00:16:16 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-06-10 00:14:58 +0100" MODIFIED_BY="[Empty name]">
<P>Hypertension is defined as a systolic blood pressure (SBP) of 140 mmHg or more or a diastolic blood pressure (DBP) of 90 mmHg or more (<LINK REF="REF-Franco-2004" TYPE="REFERENCE">Franco 2004</LINK>). In the general population, hypertension can be classified into mild (Grade 1) hypertension with a SBP of 140 mmHg to 159 mmHg and a DBP of 90 mmHg to 99 mmHg; moderate (Grade 2) hypertension with a SBP of 160 mmHg to 179 mmHg and a DBP of 100 mmHg to 109 mmHg; and severe (Grade 3) hypertension with a SBP greater than 180 mmHg and a DBP greater than 110 mmHg (<LINK REF="REF-ESH-2003" TYPE="REFERENCE">ESH 2003</LINK>). The seventh report of the Joint National Committee classified hypertension into stage 1 (SBP 140 mmHg to 159 mmHg or DBP 90 mmHg to 99 mmHg) and stage 2 (SBP 160 mmHg or more or DBP 100 mmHg or more) (<LINK REF="REF-Chobanian-2003" TYPE="REFERENCE">Chobanian 2003</LINK>).</P>
<P>Hypertensive disease occurring in approximately 7% to 9% of pregnancies is a complex clinical condition (<LINK REF="REF-Duley-2002" TYPE="REFERENCE">Duley 2002</LINK>). It can be classified as pre-existing or gestational on the basis of different diagnostic and therapeutic factors (<LINK REF="REF-Borghi-2002" TYPE="REFERENCE">Borghi 2002</LINK>; <LINK REF="REF-Chung-2001" TYPE="REFERENCE">Chung 2001</LINK>; <LINK REF="REF-Magee-2008" TYPE="REFERENCE">Magee 2008</LINK>). Almost 1% to 5% of pregnancies are complicated by pre-existing hypertension and 5% to 6% by gestational hypertension without proteinuria (<LINK REF="REF-Coppage-2005" TYPE="REFERENCE">Coppage 2005</LINK>; <LINK REF="REF-Roberts-2003" TYPE="REFERENCE">Roberts 2003</LINK>). In both conditions pregnant women are at risk of developing pre-eclampsia. Moreover, pregnant women with hypertension have higher rates of maternal and perinatal morbidity or mortality, both acute and long term (<LINK REF="REF-Livingston-2003" TYPE="REFERENCE">Livingston 2003</LINK>; <LINK REF="REF-Sibai-2002" TYPE="REFERENCE">Sibai 2002</LINK>). Adverse outcomes include premature separation of the placenta (abruption), low birthweight, and perinatal death (<LINK REF="REF-Gilbert-2007" TYPE="REFERENCE">Gilbert 2007</LINK>; <LINK REF="REF-Lindheimer-2008" TYPE="REFERENCE">Lindheimer 2008</LINK>). Women who are prone to these adverse maternal and perinatal outcomes are those who do not have regular antenatal care, those with severe hypertension, those with hypertensive-target organ damage, and those who develop pre-eclampsia (<LINK REF="REF-Livingston-2003" TYPE="REFERENCE">Livingston 2003</LINK>; <LINK REF="REF-Sibai-2002" TYPE="REFERENCE">Sibai 2002</LINK>). Risk for complications also correlates with the age of the mother, obesity and the degree of control of blood pressure (<LINK REF="REF-Lindheimer-2008" TYPE="REFERENCE">Lindheimer 2008</LINK>).</P>
<P>Accurate diagnosis is imperative for a correct therapeutic approach and hence for improving outcomes (<LINK REF="REF-Borghi-2002" TYPE="REFERENCE">Borghi 2002</LINK>). In pregnancy, mild to moderate hypertension is defined as a systolic blood pressure of 140 mmHg to 169 mmHg or a diastolic pressure of 90 mmHG to 109 mmHg (<LINK REF="REF-Ferrer-2000" TYPE="REFERENCE">Ferrer 2000</LINK>; <LINK REF="REF-Mulrow-2000" TYPE="REFERENCE">Mulrow 2000</LINK>), while a recent report used a cut-off levels for non-severe hypertension as blood pressure of 140 mmHg to 159 mmHg/90 mmHg to 109 mmHg (<LINK REF="REF-Magee-2008" TYPE="REFERENCE">Magee 2008</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-06-10 00:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>In general, antihypertensive treatment is used to reduce cardiovascular disease risk and thus morbidity and mortality rates (<LINK REF="REF-Franco-2004" TYPE="REFERENCE">Franco 2004</LINK>). A tight control of blood pressure with a goal of achieving a blood pressure less than 140/90 mmHg was found to reduce cardiovascular risks (<LINK REF="REF-Chobanian-2003" TYPE="REFERENCE">Chobanian 2003</LINK>). In patients with hypertension with diabetes or renal disease, 'very tight' control with a blood pressure goal of less than 130/80 mmHg has been recommended (<LINK REF="REF-Chobanian-2003" TYPE="REFERENCE">Chobanian 2003</LINK>).</P>
<P>The goal of blood pressure reduction is less clear in pregnant women. There is not any consensus regarding a clear goal of adjusting blood pressure in pregnant women with mild to moderate hypertension. The American Societies recommend starting therapy at a SBP of 160 or more or DBP of 105 mmHg or more, or both, without specifying a treatment goal. The Canadian guideline recently recommends that, for women without comorbid conditions, the goal is to keep systolic BP at 130 mmHg to 155 mmHg and diastolic BP at 80 mmHg to 105 mmHg, while in women with comorbid conditions a systolic BP at 130 mmHg to 139 mmHg and diastolic BP at 80 mmHg to 89 mmHg is the goal. The Australasians recommend initiation of antihypertensive therapy at BP of 160/90 mmHg, to reach a target BP of 110 to 140 over 80 to 90 mmHg (<LINK REF="REF-Magee-2001" TYPE="REFERENCE">Magee 2001</LINK>; <LINK REF="REF-Magee-2008" TYPE="REFERENCE">Magee 2008</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2011-06-09 23:22:07 +0100" MODIFIED_BY="[Empty name]">
<P>The absolute level of blood pressure during pregnancy, among other factors, determines the magnitude of maternal and perinatal risks (<LINK REF="REF-Afifi-2003" TYPE="REFERENCE">Afifi 2003</LINK>; <LINK REF="REF-Lindheimer-2008" TYPE="REFERENCE">Lindheimer 2008</LINK>; <LINK REF="REF-Magee-2001" TYPE="REFERENCE">Magee 2001</LINK>).</P>
<P>Proper management of pregnant women with high-risk chronic hypertension has been shown to improve maternal and perinatal adverse outcomes (<LINK REF="REF-Livingston-2003" TYPE="REFERENCE">Livingston 2003</LINK>; <LINK REF="REF-Sibai-2002" TYPE="REFERENCE">Sibai 2002</LINK>).</P>
<P>It has been claimed that little benefit can be gained from treating pre-existing or non-proteinuric gestational hypertension, particularly if mild or moderate (<LINK REF="REF-Chung-2001" TYPE="REFERENCE">Chung 2001</LINK>; <LINK REF="REF-Coppage-2005" TYPE="REFERENCE">Coppage 2005</LINK>; <LINK REF="REF-Montan-2004" TYPE="REFERENCE">Montan 2004</LINK>). Others have pointed out that, since treatment of pre-eclampsia leads to significant reduction in adverse maternal-fetal outcomes (<LINK REF="REF-Sibai-2003" TYPE="REFERENCE">Sibai 2003</LINK>), all pregnancies complicated by hypertension require monitoring for early detection of the onset of pre-eclampsia (<LINK REF="REF-Chung-2001" TYPE="REFERENCE">Chung 2001</LINK>).</P>
<P>Prescribing antihypertensive drugs in cases of mild to moderate (pre-existing or gestational) hypertension does not seem to reduce the risk of developing pre-eclampsia (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>; <LINK REF="REF-Montan-2004" TYPE="REFERENCE">Montan 2004</LINK>) but can reduce the risk of developing severe hypertension during pregnancy (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>).</P>
<P>On the other hand, there has been speculation that aggressive blood pressure lowering may decrease placental perfusion and jeopardize fetal well-being and might lead to fetal growth restriction while providing no extra benefit to the mother (<LINK REF="REF-Von-Dadelszen-2000" TYPE="REFERENCE">Von Dadelszen 2000</LINK>; <LINK REF="REF-Von-Dadelszen-2002" TYPE="REFERENCE">Von Dadelszen 2002</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-06-09 23:23:10 +0100" MODIFIED_BY="[Empty name]">
<P>Studies about the control of mild-moderate hypertension in pregnancy are designed to answer two core questions: the first is whether or not to prescribe antihypertensives, and the second is how tight the control of target BP should be. The value of antihypertensive drugs in pregnant women with mild-moderate hypertension continues to be an area of debate and is covered in another Cochrane systematic review (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>). The question of the target BP level remains another challenge. Therefore, many authors and pioneers in this field have declared an urgent need to conduct clinical research in this area (<LINK REF="REF-Sibai-2001" TYPE="REFERENCE">Sibai 2001</LINK>). This was the motivation to carry out this systematic review and meta-analysis in order to compare the effects of 'tight' versus 'very tight' control of mild-moderate pre-existing or non-proteinuric gestational hypertension on pregnancy outcomes.</P>
<P>Also, treatment of hypertensive women has been implicated in an increased risk of growth restriction in their infants. Treatment may not be innocuous to the fetus.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To compare tight versus very tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension for improving outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-06-10 09:42:14 +0100" MODIFIED_BY="Lynn Hampson">
<SELECTION_CRITERIA MODIFIED="2011-06-10 00:13:47 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-06-09 23:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials. We have not included quasi-randomized trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-06-09 23:24:22 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women with mild or moderate pre-existing or non-proteinuric gestational hypertension. Mild hypertension is a systolic blood pressure (SBP) of 140 mmHg to 159 mmHg and a diastolic blood pressure (DBP) of 90 mmHg to 99 mmHg; moderate hypertension is a SBP of 160 mmHg to 169 mmHg and a DBP of 100 mmHg to 109 mmHg or as defined by study authors.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-06-09 23:24:32 +0100" MODIFIED_BY="[Empty name]">
<P>Tight control of SBP below 140 mmHg and DBP below 90 mmHg (or as defined by study author) versus very tight control of blood pressure with a target level of 130/80 mmHg or less (or as defined by study author).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-06-10 00:13:47 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-04-13 14:30:41 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Severe pre-eclampsia</LI>
<LI>Eclampsia</LI>
<LI>Maternal death</LI>
<LI>Perinatal deaths</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Non-prespecified outcome</HEADING>
<UL>
<LI>Stroke</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-06-10 00:13:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Antenatal hospitalization</LI>
<LI>Maternal admission to intensive care</LI>
<LI>Women's satisfaction</LI>
<LI>Additional drugs to achieve control</LI>
<LI>Increase in dose of antihypertensive drugs to achieve control</LI>
<LI>Gestational age at delivery</LI>
<LI>Rate of induction of labor</LI>
<LI>Rate of cesarean delivery</LI>
<LI>Placental abruption</LI>
<LI>Fetal distress</LI>
<LI>Fetal growth restriction</LI>
<LI>Birthweight</LI>
<LI>Apgar score less than seven at one minute</LI>
<LI>Admission to neonatal intensive care unit</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Non-prespecified outcomes</HEADING>
<UL>
<LI>Maternal admission to high dependency care</LI>
<LI>Antenatal administration of corticosteroids</LI>
<LI>Magnesium sulfate for pre-eclampsia</LI>
<LI>Apgar score less than seven at five minutes</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-04-15 13:57:31 +0100" MODIFIED_BY="Lynn Hampson">
<ELECTRONIC_SEARCHES MODIFIED="2011-04-15 13:57:31 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register by contacting the Trials Search Co-ordinator (31 March 2011). The Cochrane Pregnancy and Childbirth Group&#8217;s Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of EMBASE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and EMBASE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
<P>In addition, we searched CENTRAL (<I>The Cochrane Library</I>) (2011, Issue 3), MEDLINE (January 1966 to 31 March 2011) and the metaRegister of Controlled Trials (<A HREF="http://www.controlled-trials.com/mrct/">mRCT</A>) (31 March 2011), both active and archived registers, using the search strategies listed in (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).<BR/>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-09-14 17:34:30 +0100" MODIFIED_BY="[Empty name]">
<P>We handsearched citation lists of relevant publications, review articles, and included studies. </P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-06-10 09:42:14 +0100" MODIFIED_BY="Lynn Hampson">
<STUDY_SELECTION MODIFIED="2009-03-25 12:15:34 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed for inclusion all potential studies we identified as a result of the search strategy. There was no disagreement regarding the selection of the studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-06-10 09:42:14 +0100" MODIFIED_BY="Lynn Hampson">
<P>We designed a form to extract data. Both review authors extracted the data using the agreed form. There were no discrepancies. We entered data into Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and checked for accuracy.</P>
<P>We did not need to contact authors of the original reports to provide further details.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-06-10 09:06:35 +0100" MODIFIED_BY="Denise Atherton">
<P>Two review authors, Ashraf Nabhan (AN) and Maged Elsedawy (ME), independently assessed risk of bias for each study using the criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). There were no disagreements on the assessment of risk of bias in the included studies. However, because AN is the coauthor of one of the included trials (<LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK>), we asked an independent external expert (<I>see</I> <LINK TAG="ACKNOWLEDGEMENTS" TYPE="SECTION">Acknowledgements</LINK>) to assess the risk of bias for the <LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK> trial.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk of bias (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI>high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number); or</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We describe for each included study the method used to conceal allocation to interventions prior to assignment and assess whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (e.g. telephone or central randomization; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk of bias (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth);</LI>
<LI>unclear risk of bias.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.1) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We consider studies to be at low risk of bias if they were blinded, or if we judge that the lack of blinding would be unlikely to affect results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low, high or unclear risk of bias for participants;</LI>
<LI>low, high or unclear risk of bias for personnel;</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3.2) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods used to blind outcome assessment as:</P>
<UL>
<LI>low, high or unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data)</HEADING>
<P>We describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomized participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information is reported, or was supplied by the trial authors, we re-include missing data in the analyses which we undertook.</P>
<P>We assessed methods as:</P>
<UL>
<LI>low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);</LI>
<LI>high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; &#8216;as treated&#8217; analysis done with substantial departure of intervention received from that assigned at randomization);</LI>
<LI>unclear risk of bias.</LI>
</UL>
<P>We categorized greater than 20% missing data as 'high' risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Selective reporting (checking for reporting bias)</HEADING>
<P>We describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk of bias (where it is clear that all of the study&#8217;s pre-specified outcomes and all expected outcomes of interest to the review have been reported);</LI>
<LI>high risk of bias (where not all the study&#8217;s pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; study fails to include results of a key outcome that would have been expected to have been reported);</LI>
<LI>unclear risk of bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)</HEADING>
<P>We describe for each included study any important concerns we have about other possible sources of bias.</P>
<P>We assessed whether each study was free of other problems that could put it at risk of bias:</P>
<UL>
<LI>low risk of other bias;</LI>
<LI>high risk of other bias;</LI>
<LI>unclear whether there is risk of other bias.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Overall risk of bias</HEADING>
<P>We have made explicit judgements about whether studies were at high risk of bias, according to the criteria given in the <I>Handbook</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). With reference to (1) to (6) above, we assessed the likely magnitude and direction of the bias and whether we considered it likely to impact on the findings. We planned to explore the impact of the level of bias through undertaking sensitivity analyses - <I>see '</I>Sensitivity analysis'. </P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-06-10 09:42:14 +0100" MODIFIED_BY="Lynn Hampson">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals (CI).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-06-10 09:06:53 +0100" MODIFIED_BY="Denise Atherton">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomized trials</HEADING>
<P>We did not identify any cluster-randomized trials for inclusion in this review. However, if we identify any cluster-randomized trials in future updates, we will include them in the analyses along with individually randomized trials. We will adjust their sample sizes<I> </I>using the methods described in the <I>Handbook,</I> using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomized trials and individually-randomized trials, we plan to synthesize the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs and the interaction between the effect of intervention and the choice of randomization unit is considered to be unlikely.</P>
<P>We will also acknowledge heterogeneity in the randomization unit and perform a subgroup analysis to investigate the effects of the randomization unit.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2011-06-09 23:30:01 +0100" MODIFIED_BY="[Empty name]">
<P>For included studies, we have noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data in the overall assessment of treatment effect by using sensitivity analysis.</P>
<P>For all outcomes, we carried out analyses, as far as possible, on an intention-to-treat basis, i.e. we attempt to include all participants randomized to each group in the analyses, and analyze all participants in the group to which they were allocated, regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomized minus any participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-06-10 09:07:49 +0100" MODIFIED_BY="Denise Atherton">
<P>We have assessed statistical heterogeneity in each meta-analysis using the T², I² and Chi² statistics. We regarded heterogeneity as substantial if I² was greater than 30% and either T² was greater than zero, or there was a low P value (less than 0.10) in the Chi² test for heterogeneity.<B> </B>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-06-09 23:30:59 +0100" MODIFIED_BY="[Empty name]">
<P>In future updates of this review, where there are 10 or more studies in the meta-analysis we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually, and use formal tests for funnel plot asymmetry. For continuous outcomes we will use the test proposed by <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>, and for dichotomous outcomes we will use the test proposed by <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>. If we detect asymmetry in any of these tests or by a visual assessment, we will perform exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-06-10 09:42:14 +0100" MODIFIED_BY="Lynn Hampson">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We have used fixed-effect meta-analysis for combining data where it is reasonable to assume that studies were estimating the same underlying treatment effect: i.e. where trials were examining the same intervention, and we judged the trials&#8217; populations and methods sufficiently similar. If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we detected substantial statistical heterogeneity, we have used random-effects meta-analysis to produce an overall summary if we considered an average treatment effect across trials clinically meaningful. We have treated the random-effects summary as the average range of possible treatment effects and we have discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we have not combined trials.</P>
<P>Where we have used random-effects analyses, we have presented the results as the average treatment effect with 95% CI, and the estimates of  T² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-06-10 09:08:35 +0100" MODIFIED_BY="Denise Atherton">
<P>If we identified substantial heterogeneity, we investigated it using subgroup analyses and sensitivity analyses. We considered whether an overall summary was meaningful, and if it was, used random-effects analysis to produce it.</P>
<P>In future updates of this review, as more data become available, we plan to carry out the following subgroup analyses.</P>
<OL>
<LI>Moderate hypertension</LI>
<LI>Pre-existing hypertension</LI>
</OL>
<P>We will restrict subgroup analysis to the primary outcomes.</P>
<P>For fixed-effect inverse variance meta-analyses, we have assessed differences between subgroups by interaction tests. For random-effects and fixed-effect meta-analyses using methods other than inverse variance, we have assessed differences between subgroups by inspection of the subgroups&#8217; CIs; we considered non-overlapping CIs indicative of a statistically significant difference in treatment effect between the subgroups.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-06-09 23:34:32 +0100" MODIFIED_BY="[Empty name]">
<P>We did not carry out any sensitivity analysis. We will carry out sensitivity analysis in future updates of this review to explore the effect of trial quality by excluding studies rated as 'high' risk of bias or 'unclear' risk of bias.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-06-10 10:36:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-06-10 09:09:13 +0100" MODIFIED_BY="Denise Atherton">
<P>
<I>See</I> <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2011-06-10 09:09:13 +0100" MODIFIED_BY="Denise Atherton">
<P>We identified two potentially eligible studies (<LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK>; <LINK REF="STD-Magee-2007" TYPE="STUDY">Magee 2007</LINK>) and one ongoing trial (<LINK REF="STD-Magee-2009" TYPE="STUDY">Magee 2009</LINK>). For further details about the ongoing study, <I>see</I> <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-06-09 23:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>We have included two studies, in which a total of 256 participants were randomized to either less tight or very tight control of blood pressure.</P>
<P>The first study (<LINK REF="STD-Magee-2007" TYPE="STUDY">Magee 2007</LINK>) included pregnant women, DBP 90 mmHg to 109 mmHg, pre-existing/gestational hypertension; live fetus(es); and 20&#8211;33+6 weeks' gestation. The target blood pressure was 100 mmHg for the less tight group and 85 mmHg for the tight group.</P>
<P>The second study (<LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK>) included pregnant women with live fetus(es) by ultrasound scan at randomization, and gestational age 20 to less than 34 weeks. Women had BP of 140 mmHg to 159 mmHg/90 mmHg to 99 mm Hg due to essential or gestational non-proteinuric hypertension. The study compared two different level of control of blood pressure, a target BP of 130 mmHg to 139 mmHg/80 mmHg to 89 mm Hg versus a target BP of less than 130/80 mm Hg. The antihypertensive used was methyldopa for all women.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2011-04-13 14:17:16 +0100" MODIFIED_BY="[Empty name]">
<P>There were no excluded studies.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-06-09 23:37:10 +0100" MODIFIED_BY="[Empty name]">
<P>Neither the participants nor the caregivers were blinded in the included trials. Lack of blinding in randomized studies can potentially predispose to some exaggeration of the intervention effects for some outcomes through multiple pathways (different expectations from the two groups and biased assessment of the effect) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This may be particularly true for subjective outcomes (e.g. women's satisfaction) or outcomes involving decision making (e.g. antenatal hospitalization).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-06-10 10:36:26 +0100" MODIFIED_BY="[Empty name]">
<P>The results are based on intention-to-treat analysis.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<P>There was no difference in the incidence of severe pre-eclampsia, when comparing the tight and very tight groups (risk ratio (RR) 1.28, 95% confidence intervals (CI) 0.97 to 1.70; two trials, 256 participants). The number of perinatal deaths was not significantly different between the tight and very tight groups (RR 1.48, 95% CI 0.25 to 8.74; two trials, 256 participants). There were no cases of eclampsia, stroke or maternal deaths reported in the results of the included trials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Non-prespecified outcomes</HEADING>
<P>No cases of stroke were reported in the one study which reported this outcome (<LINK REF="STD-Magee-2007" TYPE="STUDY">Magee 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Maternal outcomes</HEADING>
<P>More women in the tight group were hospitalized during their pregnancy (RR 2.53, 95% CI 1.14 to 5.63; one trial, 125 participants (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>)).</P>
<P>There was no evidence of a difference in induction of labour or cesarean delivery between the tight and the very tight control groups (Induction of labour, RR 1.52, 95% CI 0.78 to 2.98; one study, 125 participants (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>); cesarean delivery, RR 0.94 95% CI 0.69 to 1.28; two studies, 256 participants (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>)).</P>
<P>There were no cases of additional drugs being used in order to control blood pressure (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), or placental abruption (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) in the included trials.</P>
<P>Women's satisfaction was reported in one trial, involving 131 participants (<LINK REF="STD-Magee-2007" TYPE="STUDY">Magee 2007</LINK>). There was no difference in women's satisfaction between the tight and the very tight control group (RR 1.11, 95% CI 0.97 to 1.28 (<LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>)).</P>
<SUBSECTION>
<HEADING LEVEL="5">Non-prespecified secondary outcomes</HEADING>
<P>There was no difference in the use of magnesium sulfate for pre-eclampsia between the two groups (RR 0.82, 95% CI 0.38 to 1.77; one trial, 131 participants (<LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK>). Similarly, there was no difference in the antenatal administration of corticosteroids (RR 1.05, 95% CI 0.57 to 1.94; one trial, 131 participants (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>)). There were no cases of maternal admission to intensive care unit (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) in one included study (<LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK>).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Perinatal outcomes</HEADING>
<P>One case of antepartum fetal distress was reported in the <LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK> study; this was observed in the very tight control group (RR 0.33, 95% CI 0.01 to 7.90; 125 participants (<LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>)).</P>
<P>There was no difference in intra-uterine growth retardation (IUGR) between the tight control and the very tight control groups (RR 1.09, 95% CI 0.65 to 1.82; two trials, 256 participants (<LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>). Similarly, there was no difference in the number of admissions to the neonatal intensive care unit (NICU) between the two groups (RR 0.77, 95% CI 0.45 to 1.31; two trials, 256 participants (<LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>).</P>
<P>Gestational age at delivery had a non-significant mean difference of -0.15 weeks between the tight and very tight control groups (mean difference (MD) -0.15, 95% CI -1.52 to 1.21, random-effects (T² = 0.75, I² = 77%); two trials, 256 participants (<LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>)).</P>
<P>There was a non-significant difference in birthweight between the tight an the very tight control group (MD -100.00 grams, 95% CI -363.69 to 163.69; one trial, 125 participants (<LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>).</P>
<P>Neither of the included trials reported Apgar score at one minute.</P>
<SUBSECTION>
<HEADING LEVEL="5">Non-prespecified secondary outcomes</HEADING>
<P>Apgar score less than seven at five was reported in both of the included studies but there was no significant difference between the two groups for this outcome (RR 0.99, 95% CI 0.23 to 4.29; two trials, 251 participants (<LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>)).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-06-10 10:38:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-06-09 23:40:40 +0100" MODIFIED_BY="[Empty name]">
<P>When comparing tight and very tight control groups, there was no difference between the groups in terms of developing severe pre-eclampsia. There were no cases of eclampsia, stroke or maternal deaths. In one study, more women in the tight group were hospitalized during their pregnancy. There was no evidence of a difference in other outcome measures including fetal distress, IUGR, neonatal admission to a NICU, perinatal deaths, induction of labor and cesarean delivery, gestational age at delivery birthweight and women's satisfaction when comparing the tight with the very tight control groups.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-06-09 23:41:34 +0100" MODIFIED_BY="[Empty name]">
<P>We included two studies (256 participants with mild-moderate pre-existing or non-proteinuric gestational hypertension) in this systematic review. The participants were a low-risk group. We could not perform the subgroup analysis for two reasons: first, the included trials did not report those subgroups separately; and second, the sample size in the included trials was too small to allow a meaningful analysis. Important but rare outcomes such as eclampsia and maternal mortality can only be addressed when the trial has a suitable sample size.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-06-10 10:38:26 +0100" MODIFIED_BY="[Empty name]">
<P>Current evidence comes from two pilot studies without obvious methodological concerns apart from their non-blinded design (although the outcome assessors were blinded to the trial arms). Although all outcomes may be affected, it is likely that more subjective management decisions or assessments of outcome are more susceptible to bias arising from lack of blinding, as compared to more objective ones (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For example, antenatal hospitalization and the decision to induce labor may be more subjective, and therefore more prone to bias, than the rate of severe hypertension, eclampsia, stroke, maternal and perinatal deaths and IUGR.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-06-09 23:43:42 +0100" MODIFIED_BY="[Empty name]">
<P>We were able to identify all relevant studies and obtain all relevant data. We are not concerned that the methods used in the review could have introduced bias.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-06-10 00:17:40 +0100" MODIFIED_BY="[Empty name]">
<P>The question of how to treat non-severe, non-proteinuric, pre-existing or non-proteinuric hypertension is one of the controversial clinical issues. One grey zone is the lack of agreement on what classification of the absolute level of blood pressure should be adopted for severity. We do not believe that too much argument over the absolute level of blood pressure to determine severity is worth the effort. In fact, we should look more for associated cardiovascular risk factors and concomitant disease, such as diabetes or renal disease, to guide us in providing care. The other grey zone is the definition of the degree of control. It would helpful to propose both the classes of severity of hypertension and the various degrees of control to allow meaningful comparisons.</P>
<P>A valuable Cochrane systematic review has failed to find clear evidence to support prescribing antihypertensive drugs for the treatment of mild-moderate chronic or gestational non-proteinuric hypertension (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>). The authors found that in 28 trials, including 3200 women and comparing an antihypertensive drug with placebo/no antihypertensive drug, there was a halving in the risk of developing severe hypertension associated with the use of antihypertensive therapy (19 trials, 2409 women; RR 0.50, 95% CI 0.41 to 0.61). However, they found little evidence of a difference in the risk of pre-eclampsia. Similarly, there is no clear effect on the risk of perinatal death, preterm birth or small-for-gestational-age babies (SGA) (<LINK REF="REF-Abalos-2007" TYPE="REFERENCE">Abalos 2007</LINK>).</P>
<P>Treatment of hypertensive women has been implicated in an increased risk of growth restriction in their infants. It is not clear, based on this current review and other reviews, whether this is a consequence of lowering blood pressure during pregnancy or whether it is due to excessive blood pressure decreases or to specific drugs (<LINK REF="REF-Roberts-2003" TYPE="REFERENCE">Roberts 2003</LINK>; <LINK REF="REF-Von-Dadelszen-2000" TYPE="REFERENCE">Von Dadelszen 2000</LINK>; <LINK REF="REF-Von-Dadelszen-2002" TYPE="REFERENCE">Von Dadelszen 2002</LINK>; <LINK REF="REF-Von-Dadelszen-2005" TYPE="REFERENCE">Von Dadelszen 2005</LINK>). Treatment-induced mean difference in mean arterial pressure (MAP) was associated with lower mean birth weight. A 10 mmHg fall in MAP was associated with a 176 g decrease in birth weight. Greater mean difference in MAP with antihypertensive therapy was associated with the birth of a higher proportion of SGA infants (<LINK REF="REF-Von-Dadelszen-2000" TYPE="REFERENCE">Von Dadelszen 2000</LINK>; <LINK REF="REF-Von-Dadelszen-2002" TYPE="REFERENCE">Von Dadelszen 2002</LINK>).<BR/>
</P>
<P>Furture research protocols should consider subgroup analysis for certain groups e.g. those with renal diease or diabetes mellitus. It is a consensus of some experts that women with evidence of end-organ disease (e.g., cardiac, renal or ocular) should be treated aggressively to achieve a very tight control of blood pressure of no more than 130/80 mmHg (<LINK REF="REF-Podymow-2007" TYPE="REFERENCE">Podymow 2007</LINK>). There is insufficient evidence to support this consensus.</P>
<P>The point of when during pregnancy should we start to implement a tight or a very tight control of hypertension is not clear (<LINK REF="REF-Lindheimer-2010" TYPE="REFERENCE">Lindheimer 2010</LINK>).</P>
<P>There must be standardized means of evaluating the effect of lowering blood pressure on the fetus&#8217; ability to withstand hypoxic stress or more complex analyses of morphologic and physiologic variables in newborn when a tight or a very tight control is initiated early during the course of pregnancy. There is still insufficient evidence to advise on this point. Therefore, future research protocols should also consider when to start a tight or a very tight control during the course of gestation.</P>
<P>It is obvious that many gaps remain in our knowledge; that is why researchers eagerly await the results of an ongoing relevant study: The CHIPS trial (<LINK REF="STD-Magee-2009" TYPE="STUDY">Magee 2009</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-03-30 16:36:31 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-03-30 16:35:59 +0100" MODIFIED_BY="[Empty name]">
<P>For pregnant women with non-severe pre-existing or non-proteinuric gestational hypertension, there is insufficient evidence to determine how tight control of hypertension should be achieved to improve maternal and fetal-neonatal outcomes.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-03-30 16:36:31 +0100" MODIFIED_BY="[Empty name]">
<P>Properly conducted randomized controlled trials are required to fill this gap in our current knowledge regarding the degree of control of non-severe pre-existing or non-proteinuric gestational hypertension in pregnancy. Researchers should try to reach a consensus on the definitions of the degree of control of hypertension in pregnancy. The standardization of the degree of control is warranted to allow meaningful comparisons.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-05-12 11:26:57 +0100" MODIFIED_BY="[Empty name]">
<P>The authors of the review would like to thank Dr Wiktoria Lesniak of the Renal CRG in providing an independent assessment of the risk of bias of one of the included trials (<LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK>).</P>
<P>Amr Adel contributed to the preparation of the protocol for this review.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by three peers (an editor and two referees who are external to the editorial team), a member of the Pregnancy and Childbirth Group&#8217;s international panel of consumers and the Group&#8217;s Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-04-13 14:11:17 +0100" MODIFIED_BY="[Empty name]">
<P>Ashraf Nabhan is co-author of one of the included trials (<LINK REF="STD-El-Guindy-2008" TYPE="STUDY">El Guindy 2008</LINK>).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-04-01 14:02:37 +0100" MODIFIED_BY="[Empty name]">
<P>A Nabhan proposed the idea and the title for the review, prepared the protocol and is the guarantor of the review. Both A Nabhan and M Sedawy contributed to the full review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-06-10 09:11:38 +0100" MODIFIED_BY="Denise Atherton">
<P>The title has changed from 'Tight versus very tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension for improving outcomes' to 'Tight control of mild-moderate pre-existing or non-proteinuric gestational hypertension'.</P>
<P>The methods have been updated to reflect the latest Cochrane Handbook (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>The following primary outcome was not prespecified in our protocol, but was added in response to peer review: stroke.</P>
<P>The following secondary outcomes were not prespecified in our protocol, but were added in response to peer review:</P>
<UL>
<LI>maternal admission to high dependency care;</LI>
<LI>antenatal administration of corticosteroids;</LI>
<LI>magnesium sulfate for pre-eclampsia;</LI>
<LI>Apgar score less than seven at five minutes.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-06-10 09:47:04 +0100" MODIFIED_BY="Lynn Hampson">
<STUDIES MODIFIED="2011-06-10 00:08:52 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-06-10 00:08:52 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-El-Guindy-2008" MODIFIED="2009-03-12 12:05:10 +0000" MODIFIED_BY="[Empty name]" NAME="El Guindy 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-03-12 12:05:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Guindy AA, Nabhan AF</AU>
<TI>A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy</TI>
<SO>Journal of Perinatal Medicine</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>5</NO>
<PG>413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Magee-2007" MODIFIED="2011-06-10 00:08:52 +0100" MODIFIED_BY="[Empty name]" NAME="Magee 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-12-14 00:02:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>CHIPS Study Group</AU>
<TI>The CHIPS Pilot Trial (Control of Hypertension in Pregnancy Study) [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>Suppl 1</NO>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-14 00:02:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cote AM</AU>
<TI>The CHIPS pilot trial (control of hypertension in pregnancy study) [abstract]</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>178</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-14 00:02:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magee LA, Hannah M, Von Dadelszen P, Gafni A, Helewa M, Logan AG, et al</AU>
<TI>Control of hypertension in pregnancy &amp; small for gestational age infants (CHIPS): a randomised controlled trial of a dBP of 100 vs 85mmHg for mild-moderate pre-existing or non-proteinuric gestational hypertension</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>Suppl 1</NO>
<PG>Abstract no: P169</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-10 00:08:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magee LA, Hannah ME, Von Dadelszen P, Gafni A, Gruslin A, Helewa M, et al</AU>
<TI>The CHIPS trial (control of hypertension in pregnancy study) [abstract]</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>Suppl 1</NO>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-10 00:08:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Magee LA, Hannah ME, Von Dadelszen P, Gafni A, Helewa M, Logan AG, et al</AU>
<TI>Control of hypertension in pregnancy and small for gestational age infants (CHIPS): a randomised controlled trial of a diastolic BP (DBP) of 100 vs 85 mmhg for mild-moderate pre-existing hypertension or non-proteinuric gestational hypertension</TI>
<SO>XVI FIGO World Congress of Obstetrics &amp; Gynecology (Book 2 ); 2000 Sept 3-8; Washington DC, USA</SO>
<YR>2000</YR>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-10 00:08:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Magee LA, Von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al</AU>
<TI>The control of hypertension in pregnancy study pilot trial</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2007</YR>
<VL>114</VL>
<NO>6</NO>
<PG>770-e20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-06-10 00:08:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magee LA, Von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, et al</AU>
<TI>Women's views of their experiences in the CHIPS (control of hypertension in pregnancy study) pilot trial</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>4</NO>
<PG>371-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-12-14 00:02:37 +0000" MODIFIED_BY="[Empty name]"/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2011-04-15 13:42:42 +0100" MODIFIED_BY="Lynn Hampson">
<STUDY DATA_SOURCE="MIX" ID="STD-Magee-2009" MODIFIED="2011-04-15 13:42:42 +0100" MODIFIED_BY="Lynn Hampson" NAME="Magee 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-27 02:24:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magee L, for the CHIPS Study Group</AU>
<TI>The CHIPS trial (control of hypertension in pregnancy study)</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>4</NO>
<PG>515</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-04-15 13:42:42 +0100" MODIFIED_BY="Lynn Hampson" PRIMARY="YES" TYPE="OTHER">
<AU>Magee LA for the CHIPS Study Group</AU>
<TI>09PRT/3980: The CHIPS Trial (Control of Hypertension In Pregnancy Study) (ISRCTN 71416914, MCT-87522)</TI>
<SO>http://www.thelancet.com/protocol-reviews/09PRT-3980</SO>
<YR>(accessed 15 April 2011)</YR>
<IDENTIFIERS MODIFIED="2011-04-15 11:51:12 +0100" MODIFIED_BY="Lynn Hampson"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-06-10 09:47:04 +0100" MODIFIED_BY="Lynn Hampson">
<ADDITIONAL_REFERENCES MODIFIED="2011-06-10 09:47:04 +0100" MODIFIED_BY="Lynn Hampson">
<REFERENCE ID="REF-Abalos-2007" MODIFIED="2009-03-12 12:05:35 +0000" MODIFIED_BY="[Empty name]" NAME="Abalos 2007" TYPE="COCHRANE_REVIEW">
<AU>Abalos E, Duley L, Steyn DW, Henderson-Smart DJ</AU>
<TI>Antihypertensive drug therapy for mild to moderate hypertension during pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-03-12 12:05:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-12 12:05:35 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002252.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Afifi-2003" NAME="Afifi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Afifi Y, Churchill D</AU>
<TI>Pharmacological treatment of hypertension in pregnancy</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>21</NO>
<PG>1745-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borghi-2002" MODIFIED="2009-03-12 12:06:25 +0000" MODIFIED_BY="[Empty name]" NAME="Borghi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Borghi C, Esposti DD, Cassani A, Immordino V, Bovicelli L, Ambrosioni E</AU>
<TI>The treatment of hypertension in pregnancy</TI>
<SO>Journal of Hypertension. Supplement</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>2</NO>
<PG>S52-S56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chobanian-2003" MODIFIED="2011-04-15 13:42:50 +0100" MODIFIED_BY="Lynn Hampson" NAME="Chobanian 2003" TYPE="JOURNAL_ARTICLE">
<AU>Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al</AU>
<TI>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<NO>19</NO>
<PG>2560-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chung-2001" MODIFIED="2009-01-31 12:10:01 +0000" MODIFIED_BY="[Empty name]" NAME="Chung 2001" TYPE="JOURNAL_ARTICLE">
<AU>Chung NA, Beevers DG, Lip GY</AU>
<TI>Management of hypertension in pregnancy</TI>
<SO>American Journal of Cardiovascular Drugs</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>4</NO>
<PG>253-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coppage-2005" NAME="Coppage 2005" TYPE="JOURNAL_ARTICLE">
<AU>Coppage KH, Sibai BM</AU>
<TI>Treatment of hypertensive complications in pregnancy</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>6</NO>
<PG>749-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duley-2002" MODIFIED="2009-03-12 12:10:32 +0000" MODIFIED_BY="[Empty name]" NAME="Duley 2002" NOTES="&lt;p&gt;no volume&lt;/p&gt;" NOTES_MODIFIED="2009-03-12 12:10:32 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Duley L</AU>
<TI>Pre-eclampsia and hypertension</TI>
<SO>Clinical Evidence</SO>
<YR>2002</YR>
<VL>Jun</VL>
<NO>7</NO>
<PG>1296-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2011-04-13 10:38:35 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ESH-2003" MODIFIED="2009-03-12 12:14:02 +0000" MODIFIED_BY="[Empty name]" NAME="ESH 2003" TYPE="JOURNAL_ARTICLE">
<AU>European Society of Hypertension-European Society of Cardiology Guidelines Committee</AU>
<TI>2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension</TI>
<SO>Journal of Hypertension</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>6</NO>
<PG>1011-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferrer-2000" MODIFIED="2011-06-10 09:41:31 +0100" MODIFIED_BY="Lynn Hampson" NAME="Ferrer 2000" NOTES="&lt;p&gt;Ferrer, R L&lt;br&gt;Sibai, B M&lt;br&gt;Mulrow, C D&lt;br&gt;Chiquette, E&lt;br&gt;Stevens, K R&lt;br&gt;Cornell, J&lt;br&gt;Research Support, Non-U.S. Gov't&lt;br&gt;Review&lt;br&gt;United states&lt;br&gt;Obstetrics and gynecology&lt;br&gt;Obstet Gynecol. 2000 Nov;96(5 Pt 2):849-60.&lt;/p&gt;" NOTES_MODIFIED="2011-06-10 09:41:31 +0100" NOTES_MODIFIED_BY="Lynn Hampson" TYPE="OTHER">
<AU>Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J</AU>
<TI>Management of mild chronic hypertension during pregnancy: a review</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2000</YR>
<VL>96</VL>
<NO>5 Pt 2</NO>
<PG>849-60</PG>
<IDENTIFIERS MODIFIED="2011-06-10 09:41:31 +0100" MODIFIED_BY="Lynn Hampson"/>
</REFERENCE>
<REFERENCE ID="REF-Franco-2004" NAME="Franco 2004" TYPE="JOURNAL_ARTICLE">
<AU>Franco V, Oparil S, Carretero OA</AU>
<TI>Hypertensive therapy: Part I</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>109</VL>
<NO>24</NO>
<PG>2953-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbert-2007" MODIFIED="2011-04-15 13:50:40 +0100" MODIFIED_BY="Lynn Hampson" NAME="Gilbert 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gilbert WM, Young AL, Danielson B</AU>
<TI>Pregnancy outcome in women with chronic hypertension: a population based study</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>2007</YR>
<VL>52</VL>
<PG>1046-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2011-04-13 10:38:35 +0100" MODIFIED_BY="[Empty name]" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-04-13 10:29:09 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindheimer-2008" MODIFIED="2011-04-15 13:46:04 +0100" MODIFIED_BY="Lynn Hampson" NAME="Lindheimer 2008" TYPE="JOURNAL_ARTICLE">
<AU>Lindheimer MD, Taler SJ, Cunningham FG</AU>
<TI>Hypertension in pregnancy</TI>
<SO>Journal of the American Society of Hypertension</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>6</NO>
<PG>484&#8211;94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindheimer-2010" MODIFIED="2011-04-15 13:46:47 +0100" MODIFIED_BY="Lynn Hampson" NAME="Lindheimer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lindheimer MD, Taler SJ, Cunningham FG</AU>
<TI>Hypertension in pregnancy</TI>
<SO>Journal of the American Society of Hypertension</SO>
<YR>2010</YR>
<VL>4</VL>
<NO>2</NO>
<PG>68-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livingston-2003" NAME="Livingston 2003" TYPE="JOURNAL_ARTICLE">
<AU>Livingston JC, Maxwell BD, Sibai BM</AU>
<TI>Chronic hypertension in pregnancy</TI>
<SO>Minerva Ginecologica</SO>
<YR>2003</YR>
<VL>55</VL>
<NO>1</NO>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magee-2001" NAME="Magee 2001" TYPE="JOURNAL_ARTICLE">
<AU>Magee LA</AU>
<TI>Drugs in pregnancy. Antihypertensives</TI>
<SO>Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>6</NO>
<PG>827-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Magee-2008" MODIFIED="2011-06-10 00:10:08 +0100" MODIFIED_BY="[Empty name]" NAME="Magee 2008" TYPE="JOURNAL_ARTICLE">
<AU>Magee LA, Helewa M, Moutquin JM, Van Dadelszen P, for the Hypertension Guideline Committee.</AU>
<TI>Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. SOGC Clinical Practice Guideline, No. 206</TI>
<SO>Journal of Obstetrics and Gynaecolology Canada.</SO>
<YR>2008</YR>
<VL>30</VL>
<PG>S1&#8211;S48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montan-2004" NAME="Montan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Montan S</AU>
<TI>Drugs used in hypertensive diseases in pregnancy</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>2</NO>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-2000" MODIFIED="2011-06-10 09:47:04 +0100" MODIFIED_BY="Lynn Hampson" NAME="Mulrow 2000" NOTES="&lt;p&gt;Mulrow, C D&lt;br&gt;Chiquette, E&lt;br&gt;Ferrer, R L&lt;br&gt;Sibai, B M&lt;br&gt;Stevens, K R&lt;br&gt;Harris, M&lt;br&gt;Montgomery, K A&lt;br&gt;Stamm, K&lt;br&gt;United states&lt;br&gt;Evidence report/technology assessment (Summary)&lt;br&gt;Evid Rep Technol Assess (Summ). 2000 Aug;(14):1-4.&lt;/p&gt;" NOTES_MODIFIED="2011-06-10 09:47:04 +0100" NOTES_MODIFIED_BY="Lynn Hampson" TYPE="BOOK">
<AU>Mulrow CD, Chiquette E, Ferrer RL, Sibai BM, Stevens KR, Harris M, et al</AU>
<SO>Management of chronic hypertension during pregnancy. Evidence Report/Technology Assessment No. 14 (Summary)</SO>
<YR>2000</YR>
<PB>Agency for Healthcare Research and Quality</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS MODIFIED="2011-06-10 09:42:02 +0100" MODIFIED_BY="Lynn Hampson"/>
</REFERENCE>
<REFERENCE ID="REF-Podymow-2007" MODIFIED="2011-06-10 00:10:27 +0100" MODIFIED_BY="[Empty name]" NAME="Podymow 2007" TYPE="JOURNAL_ARTICLE">
<AU>Podymow T, August P</AU>
<TI>Hypertension in pregnancy</TI>
<SO>Advances in Chronic Kidney Disease</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>2</NO>
<PG>178-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-06-10 09:42:18 +0100" MODIFIED_BY="Lynn Hampson" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2003" MODIFIED="2011-06-10 00:10:47 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 2003" TYPE="JOURNAL_ARTICLE">
<AU>Roberts JM, Pearson GD, Cutler JA, Lindheimer MD</AU>
<TI>Summary of the NHLBI Working Group on research on hypertension during pregnancy</TI>
<SO>Hypertension in Pregnancy</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>2</NO>
<PG>109-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibai-2001" NAME="Sibai 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM</AU>
<TI>Antihypertensive drugs during pregnancy</TI>
<SO>Seminars in Perinatology</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>3</NO>
<PG>159-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibai-2002" NAME="Sibai 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM</AU>
<TI>Chronic hypertension in pregnancy</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>2</NO>
<PG>369-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibai-2003" NAME="Sibai 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sibai BM</AU>
<TI>Diagnosis and management of gestational hypertension and preeclampsia</TI>
<SO>Obstetrics &amp; Gynecology</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>1</NO>
<PG>181-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Dadelszen-2000" MODIFIED="2011-06-10 00:11:05 +0100" MODIFIED_BY="[Empty name]" NAME="Von Dadelszen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA</AU>
<TI>Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<PG>87-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Dadelszen-2002" NAME="Von Dadelszen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Von Dadelszen P, Magee LA</AU>
<TI>Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis</TI>
<SO>Journal of Obstetrics and Gynaecology Canada: JOGC</SO>
<YR>2002</YR>
<VL>24</VL>
<NO>12</NO>
<PG>941-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Von-Dadelszen-2005" MODIFIED="2011-06-10 00:11:18 +0100" MODIFIED_BY="[Empty name]" NAME="Von Dadelszen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Von Dadelszen P, Menzies J, Magee LA</AU>
<TI>The complications of hypertension in pregnancy</TI>
<SO>Minerva Medica</SO>
<YR>2005</YR>
<VL>96</VL>
<NO>4</NO>
<PG>287-302</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-03-27 19:02:08 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-06-10 10:40:50 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-06-10 09:16:59 +0100" MODIFIED_BY="Denise Atherton" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-06-10 09:13:54 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-El-Guindy-2008">
<CHAR_METHODS MODIFIED="2010-12-15 15:45:09 +0000" MODIFIED_BY="[Empty name]">
<P>Women were randomly assigned to either tight BP target group (63 women) or less tight BP target group (62 women) according to a computer-generated randomization list and contained in a set of consecutively numbered sealed opaque envelopes. After a participant was found eligible and consented to participate, the numbered envelope was opened to determine the treatment group. The obstetric resident in the antenatal clinic assessed women for eligibility. The principal investigator assigned participants to their groups.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-09 23:49:50 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women with live fetus(es) by ultrasound scan at randomization, and gestational age 20 to &lt; 34 weeks. Women had BP of 140 mmHg to 159 mmHg/90 mmHg to 99 mmHg due to essential or gestational non-proteinuric hypertension.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-10 09:13:54 +0100" MODIFIED_BY="Denise Atherton">
<P>1 arm of the trial assigned participants to a target BP of 130 mmHg to 139 mmHg/80 mmHg to 89 mmHg; the target in the comparison group was a BP of &lt; 130/80 mmHg. The antihypertensive used was methyldopa for all women.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-09 23:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>The main outcome measure was severe hypertension (defined as systolic BP G160 mmHg and/or diastolic BP G100) w5x. BP was measured at baseline and twice weekly during follow-up. Other outcome measures included development of proteinuria, amniotic fluid volume, non-stress test, fetal growth restriction, birthweight, gestational age at delivery, rates of preterm birth (before completed 37 weeks&#8217; gestation), length of neonatal stay in hospital, stillbirth, neonatal death, respiratory distress (after initial resuscitation, need for intubation and ventilation by endotracheal tube for 24 h starting within 72 h after birth), eclampsia and maternal death. Laboratory studies including platelet count, serum creatinine and serum uric acid were assessed at baseline and at delivery for all women.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-13 14:02:16 +0100" MODIFIED_BY="[Empty name]">
<P>Egypt.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-10 09:16:34 +0100" MODIFIED_BY="Denise Atherton" STUDY_ID="STD-Magee-2007">
<CHAR_METHODS MODIFIED="2011-06-10 00:18:25 +0100" MODIFIED_BY="[Empty name]">
<P>The CHIPS pilot trial was a multicenter, open randomized controlled trial, with prognostic stratification for type of non-proteinuric hypertension.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-09 23:52:56 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion: pregnant women, DBP 90 mmHg to 109 mmHg, pre-existing/gestational hypertension; live fetus(es); and 20&#8211;33+6 weeks' gestation. Exclusion: SBP &#8805;170 mmHg and proteinuria, contraindication or major fetal anomaly.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-09 23:53:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomization to less tight (target DBP 100 mmHg) or tight (target DBP 85 mmHg) blood pressure control. The treatment goal was applied from the time of randomization until delivery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-10 09:16:34 +0100" MODIFIED_BY="Denise Atherton">
<P>Primary: mean DBP at 28, 32 and 36 weeks. Secondary: clinician compliance and women&#8217;s satisfaction.</P>
<P>Serious perinatal complications, the primary outcome for the planned CHIPS trial, were de&#64257;ned as stillbirth, neonatal death or 1 or more of the following: birthweight &lt; 3rd centile for gestational age and sex; 18 respiratory distress; bronchopulmonary dysplasia; intraventricular hemorrhage grade 3 or 4; cystic periventricular hemorrhage; retinopathy of prematurity stage 3&#8211;5 in 1 or both eyes; or NEC. Serious maternal complications, the secondary outcome for the planned CHIPS trial, were defined as death or 1 or more life-threatening maternal complications including the following: stroke; eclampsia; severe HELLP syndrome; or end-organ failure. Other fetomaternal outcomes included placental abruption; maternal syndrome of pre-eclampsia; and adverse maternal symptoms believed to re&#64258;ect pre-eclampsia.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-10 09:16:12 +0100" MODIFIED_BY="Denise Atherton">
<P>17 obstetric centres in Canada, Australia, New Zealand, and UK.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>DBP: diastolic blood pressure<BR/>h: hour<BR/>HELLP: hemolysis, elevated liver enzymes and low platelet count<BR/>NEC: necrotizing enterocolitis<BR/>SBP: systolic blood pressure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-12-14 00:02:37 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2011-06-10 10:40:50 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2011-06-10 10:40:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Magee-2009">
<CHAR_STUDY_NAME MODIFIED="2011-06-09 23:56:06 +0100" MODIFIED_BY="[Empty name]">
<P>The CHIPS Trial (Control of Hypertension In Pregnancy Study).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2011-06-10 00:12:42 +0100" MODIFIED_BY="[Empty name]">
<P>An international multicentre randomized trial of 1028 women (514 per group) from 50 tertiary and community centres.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-10 10:40:50 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: pre-existing/gestational hypertension; office DBP 90 mmHg to 105 mmHg (or 85 mmHg to 105 mmHg if on antihypertensives); live fetus; and 14-33 weeks' gestation. Exclusion criteria: severe systolic hypertension (&#8805; 160 mmHg); proteinuria; contraindication to either group of the trial or to prolongation of pregnancy; use of an angiotensin-converting-enzyme inhibitor at or after 14 weeks' gestation; known multiple gestation; lethal/major fetal anomaly; plan to terminate pregnancy; or previous participation in CHIPS.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-09 23:56:27 +0100" MODIFIED_BY="[Empty name]">
<P>Eligible women will be randomized centrally to either 'less tight' control (aiming for DBP 100mmHg) or 'tight' control (aiming for DBP 85mmHg) of their hypertension.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-10 09:16:39 +0100" MODIFIED_BY="Denise Atherton">
<P>Primary: pregnancy loss (miscarriage, stillbirth, or neonatal death) or high level neonatal care for &gt; 48 hours in the first 28 days of life or prior to primary hospital discharge, whichever is later.</P>
<P>Secondary: 1/more serious maternal complication(s) until six weeks postpartum. Death or 1 or more life-threatening maternal complications: adverse neurological complications (stroke, eclampsia and/or blindness); end-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischemia/infarction, renal failure, coagulopathy, and/or transfusion); or both.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-06-10 10:40:01 +0100" MODIFIED_BY="[Empty name]">
<P>April 2009.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-06-10 10:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>Dr  Laura Ann  Magee.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-10 10:40:14 +0100" MODIFIED_BY="[Empty name]">
<P>ISRCTN:<B> </B>NCT01192412. Serial number at source MCT-87522.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>DBP: diastolic blood pressure</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-06-09 23:52:11 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-04-13 13:38:52 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 12:57:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>Computer-generated randomization list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-13 13:38:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>Random permuted blocks of variable size and a toll-free 24-hour centrally controlled computerized randomization service (at the Data Coordinating Centre, Maternal, Infant and Reproductive Health Research Unit).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-04-13 13:39:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 12:57:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>Consecutively numbered sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-13 13:39:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>Centrally controlled computerized randomization service.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-04-13 13:38:36 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-04-13 13:38:14 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-13 13:37:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>Caregiver: not blinded.</P>
<P>Particpants: not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-04-13 13:38:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>Caregiver: not blinded.</P>
<P>Particpants: not blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-04-13 13:38:07 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-13 13:37:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>Outcome assessor: blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-04-13 13:38:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>Outcome assessor: blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2011-06-09 23:52:11 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-09 23:52:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>Total losses: 5/125 (3/63 missing from intervention group; 2/62 missing from control group; missing outcome data balanced in numbers across intervention groups; all did not complete follow-up).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-13 13:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>Total losses: 1/132 (lost neonatal and maternal forms).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-04-13 13:39:03 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-03 11:11:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-13 13:39:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes have been reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-04-13 13:39:04 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-03-25 12:58:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-El-Guindy-2008">
<DESCRIPTION>
<P>The non-blinded design potentially creates conditions for performance and detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-13 13:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Magee-2007">
<DESCRIPTION>
<P>The non-blinded design potentially creates conditions for performance and detection bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-06-10 00:12:02 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-05-12 11:09:44 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Primary outcome measures</NAME>
<DICH_OUTCOME CHI2="0.6228147084248852" CI_END="1.6985041748348284" CI_START="0.9711249341563863" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2843129505501454" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="46" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.23006661868058345" LOG_CI_START="-0.012724894989584963" LOG_EFFECT_SIZE="0.10867086184549926" METHOD="MH" MODIFIED="2010-12-14 02:06:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4300034496843492" P_Q="1.0" P_Z="0.0793418801776009" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="100.0" Z="1.7545174636989502">
<NAME>Severe pre-eclampsia</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9314246178034473" CI_START="0.8282629964396699" EFFECT_SIZE="1.5582010582010581" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.4670787306910613" LOG_CI_START="-0.08183174079130873" LOG_EFFECT_SIZE="0.1926234949498763" MODIFIED="2010-12-14 02:06:54 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.3224327280993996" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.10396286414962135" WEIGHT="26.093967370684204"/>
<DICH_DATA CI_END="1.6014355444374373" CI_START="0.880722837572212" EFFECT_SIZE="1.1876114081996434" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="34" LOG_CI_END="0.20450946360023084" LOG_CI_START="-0.05516074204329635" LOG_EFFECT_SIZE="0.07467436077846723" MODIFIED="2010-12-14 00:20:28 +0000" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.1525315641832563" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.02326587807219084" WEIGHT="73.9060326293158"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-14 02:07:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Eclampsia</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 02:07:05 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 00:20:59 +0000" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.0" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-12-14 02:07:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Maternal death</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 02:07:18 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 00:21:12 +0000" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.0" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4692620702721249" CI_END="8.743441142015904" CI_START="0.249518490698513" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.477041041158671" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="31.938622779883776" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.9416823908566558" LOG_CI_START="-0.6028972652278676" LOG_EFFECT_SIZE="0.16939256281439413" METHOD="MH" MODIFIED="2011-04-13 11:03:32 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.22546247514439566" P_Q="1.0" P_Z="0.667272224852706" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="99.99999999999999" Z="0.4298947238587522">
<NAME>Perinatal deaths</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.49038175594755" CI_START="0.2410663895621159" EFFECT_SIZE="4.921875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.002124496082725" LOG_CI_START="-0.6178633364712983" LOG_EFFECT_SIZE="0.6921305798057134" MODIFIED="2010-12-14 02:07:28 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="1.5389938219911683" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="2.368501984126984" WEIGHT="25.006610064925525"/>
<DICH_DATA CI_END="7.915769223419725" CI_START="0.013620800498994726" EFFECT_SIZE="0.3283582089552239" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8984931242841903" LOG_CI_START="-1.8657973680414306" LOG_EFFECT_SIZE="-0.48365212187862017" MODIFIED="2010-12-14 00:15:23 +0000" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="1.6237579186506907" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="2.636589778380823" WEIGHT="74.99338993507446"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-12 11:09:44 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="65" WEIGHT="0.0" Z="0.0">
<NAME>Stroke</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight contro</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-19 23:24:26 +0000" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.0" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-06-10 00:12:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Secondary outcome measures</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.629374987533994" CI_START="1.1376037922875744" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5306122448979593" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.7504601791261063" LOG_CI_START="0.05599103114133646" LOG_EFFECT_SIZE="0.4032256051337214" METHOD="MH" MODIFIED="2011-05-12 11:17:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.022845703956133376" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="2.276005106921741">
<NAME>Antenatal hospitalization</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.629374987533994" CI_START="1.1376037922875744" EFFECT_SIZE="2.5306122448979593" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="7" LOG_CI_END="0.7504601791261063" LOG_CI_START="0.05599103114133646" LOG_EFFECT_SIZE="0.4032256051337214" MODIFIED="2010-12-14 02:08:34 +0000" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.4079346152039785" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.166410650281618" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-12 11:17:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Maternal admission to ICU</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 02:08:46 +0000" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.0" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-12 11:12:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>Additional drugs to achieve control</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 02:08:55 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.0" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.979687398972781" CI_START="0.7763258512607252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.520923520923521" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.4741707043372305" LOG_CI_START="-0.10995595180778833" LOG_EFFECT_SIZE="0.1821073762647211" METHOD="MH" MODIFIED="2011-05-12 11:13:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.22167850299377845" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="99.99999999999999" Z="1.2220770788084891">
<NAME>Induction of labor</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9796873989727803" CI_START="0.7763258512607253" EFFECT_SIZE="1.520923520923521" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="11" LOG_CI_END="0.4741707043372304" LOG_CI_START="-0.10995595180778826" LOG_EFFECT_SIZE="0.1821073762647211" MODIFIED="2010-12-14 02:09:15 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.343118889293165" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.11773057218977521" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5335719487724455" CI_END="1.2798934811798757" CI_START="0.6931268600029707" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9418750181146534" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="46" I2="0.0" I2_Q="100.0" ID="CMP-002.05" LOG_CI_END="0.1071738271004025" LOG_CI_START="-0.15918727107781228" LOG_EFFECT_SIZE="-0.02600672198870487" METHOD="MH" MODIFIED="2011-05-12 11:13:40 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.46510907624234743" P_Q="0.0" P_Z="0.7019197079808515" Q="1.9668158375104474E-33" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="100.0" Z="0.38273035216053464">
<NAME>Cesarean delivery</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.698854312606022" CI_START="0.5360720817578633" EFFECT_SIZE="1.2028218694885362" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.4311794414520389" LOG_CI_START="-0.2707768099248942" LOG_EFFECT_SIZE="0.08020131576357235" MODIFIED="2010-12-14 02:09:25 +0000" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.4123325767982947" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.17001815388912161" WEIGHT="19.570939616944248"/>
<DICH_DATA CI_END="1.2106358917305788" CI_START="0.6373085259348432" EFFECT_SIZE="0.8783783783783784" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="37" LOG_CI_END="0.08301354529887876" LOG_CI_START="-0.19565027147512" LOG_EFFECT_SIZE="-0.056318363088120604" MODIFIED="2010-12-14 00:12:31 +0000" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.16368850538118673" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.026793926793926795" WEIGHT="80.42906038305576"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-05-12 11:14:01 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="0.0" Z="0.0">
<NAME>Placental abruption</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 02:09:42 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-12-14 00:13:01 +0000" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.0" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9441162753218573" CI_START="0.5676413880923451" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0505050505050506" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.28872223601233854" LOG_CI_START="-0.24592594660987763" LOG_EFFECT_SIZE="0.02139814470123048" METHOD="MH" MODIFIED="2011-06-10 00:11:44 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.8753341465834047" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="65" WEIGHT="100.0" Z="0.15688669414227852">
<NAME>Antenatal administration of corticosteroids</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9441162753218573" CI_START="0.5676413880923451" EFFECT_SIZE="1.0505050505050506" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.28872223601233854" LOG_CI_START="-0.24592594660987763" LOG_EFFECT_SIZE="0.02139814470123048" MODIFIED="2011-03-30 16:23:10 +0100" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.3140549890234768" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.09863053613053611" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7656993342972633" CI_START="0.381469303875936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8207070707070707" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.24691675327755253" LOG_CI_START="-0.4185404031708284" LOG_EFFECT_SIZE="-0.08581182494663792" METHOD="MH" MODIFIED="2011-06-10 00:11:53 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.6132208058401916" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="65" WEIGHT="99.99999999999999" Z="0.5054813362912939">
<NAME>Magnesium sulfate for pre-eclampsia</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7656993342972636" CI_START="0.381469303875936" EFFECT_SIZE="0.8207070707070707" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.24691675327755258" LOG_CI_START="-0.4185404031708284" LOG_EFFECT_SIZE="-0.08581182494663792" MODIFIED="2011-03-30 16:24:59 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.39089282776382944" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.15279720279720282" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.903364776262229" CI_START="0.013622807332438333" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.328125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.8978120270691563" LOG_CI_START="-1.8657333855690923" LOG_EFFECT_SIZE="-0.4839606792499679" METHOD="MH" MODIFIED="2011-05-12 11:15:07 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.49241678443083625" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" WEIGHT="99.99999999999999" Z="0.6864699938894356">
<NAME>Fetal distress</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.903364776262229" CI_START="0.013622807332438333" EFFECT_SIZE="0.328125" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8978120270691563" LOG_CI_START="-1.8657333855690923" LOG_EFFECT_SIZE="-0.4839606792499679" MODIFIED="2010-12-14 02:11:26 +0000" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="1.6233202551541241" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="2.6351686507936507" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.40963656206007976" CI_END="1.8241799736098567" CI_START="0.6463367641548159" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0858335882532886" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.2610676836030404" LOG_CI_START="-0.1895411403554226" LOG_EFFECT_SIZE="0.03576327162380888" METHOD="MH" MODIFIED="2011-05-12 11:15:32 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.5221540446970676" P_Q="1.0" P_Z="0.7557160929439382" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="100.00000000000001" Z="0.31111119279124466">
<NAME>IUGR</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.13028298636007" CI_START="0.12260526599194507" EFFECT_SIZE="2.953125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8520545365084813" LOG_CI_START="-0.9114908761297672" LOG_EFFECT_SIZE="0.470281830189357" MODIFIED="2010-12-14 02:10:40 +0000" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="1.6233202551541241" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="2.6351686507936507" WEIGHT="2.5646986846130315"/>
<DICH_DATA CI_END="1.7546823189072485" CI_START="0.6124817204624912" EFFECT_SIZE="1.036682615629984" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.2441984999276854" LOG_CI_START="-0.2129068683034072" LOG_EFFECT_SIZE="0.015645815812139106" MODIFIED="2010-12-14 00:18:52 +0000" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.26850595600700905" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.07209544841123788" WEIGHT="97.43530131538698"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6735575520526766" CI_END="1.3143442030911985" CI_START="0.44638143135543534" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7659626927400369" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" I2="40.24705043615231" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="0.11870911402716473" LOG_CI_START="-0.3502938795444869" LOG_EFFECT_SIZE="-0.11579238275866105" METHOD="MH" MODIFIED="2011-05-12 11:15:51 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.19578278285276018" P_Q="1.0" P_Z="0.3331477880268535" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" WEIGHT="100.00000000000001" Z="0.9677929693486294">
<NAME>Admission to NICU</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="100.49038175594755" CI_START="0.2410663895621159" EFFECT_SIZE="4.921875" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.002124496082725" LOG_CI_START="-0.6178633364712983" LOG_EFFECT_SIZE="0.6921305798057134" MODIFIED="2010-12-14 02:10:24 +0000" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="1.5389938219911683" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" VAR="2.368501984126984" WEIGHT="2.2227406731850095"/>
<DICH_DATA CI_END="1.175350962561567" CI_START="0.3836263514096785" EFFECT_SIZE="0.6714876033057852" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" LOG_CI_END="0.07016756732684253" LOG_CI_START="-0.4160915686579186" LOG_EFFECT_SIZE="-0.17296200066553807" MODIFIED="2010-12-14 00:14:00 +0000" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.2856310234989918" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.08158508158508158" WEIGHT="97.777259326815"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.272088339857656" CI_END="1.214785365682662" CI_START="-1.5212226406452851" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.15321863748131156" ESTIMABLE="YES" I2="76.59224434405493" I2_Q="0.0" ID="CMP-002.12" MODIFIED="2011-05-12 11:16:49 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.03874345617894004" P_Q="1.0" P_Z="0.8262457011142854" Q="0.0" RANDOM="YES" SCALE="32.43788630573243" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.7506039945717443" TOTALS="YES" TOTAL_1="129" TOTAL_2="127" UNITS="" WEIGHT="100.0" Z="0.21951910267010688">
<NAME>Gestational age at delivery</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.028635480233028532" CI_START="-1.57136451976698" EFFECT_SIZE="-0.8000000000000043" ESTIMABLE="YES" MEAN_1="35.8" MEAN_2="36.6" MODIFIED="2010-12-14 02:10:12 +0000" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="2.2" SD_2="2.2" SE="0.3935605581793342" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" WEIGHT="53.801331248664994"/>
<CONT_DATA CI_END="1.6804755409603065" CI_START="-0.48047554096030365" EFFECT_SIZE="0.6000000000000014" ESTIMABLE="YES" MEAN_1="36.9" MEAN_2="36.3" MODIFIED="2010-12-14 00:23:36 +0000" MODIFIED_BY="[Empty name]" ORDER="24" SD_1="3.0" SD_2="3.3" SE="0.5512731608758927" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" WEIGHT="46.198668751335006"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="163.68879673115526" CI_START="-363.68879673115526" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-100.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" MODIFIED="2011-05-12 11:18:37 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.0" P_Q="1.0" P_Z="0.45730807533345863" Q="0.0" RANDOM="NO" SCALE="916.6355289752231" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.7432867868627508">
<NAME>Birthweight</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<CONT_DATA CI_END="163.68879673115526" CI_START="-363.68879673115526" EFFECT_SIZE="-100.0" ESTIMABLE="YES" MEAN_1="2900.0" MEAN_2="3000.0" MODIFIED="2010-12-14 02:10:00 +0000" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="700.0" SD_2="800.0" SE="134.5375725325051" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2806326626846753" CI_START="0.9706552981572864" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1149228130360205" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="53" I2="0.0" I2_Q="100.0" ID="CMP-002.14" LOG_CI_END="0.10742457436056735" LOG_CI_START="-0.012934970592884464" LOG_EFFECT_SIZE="0.04724480188384145" METHOD="MH" MODIFIED="2011-05-12 11:20:46 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="0.0" P_Z="0.123879605011435" Q="3.8530461192725535E-32" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="66" TOTAL_2="65" WEIGHT="100.0" Z="1.5386915958326532">
<NAME>Women satisfaction</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours very tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2806326626846753" CI_START="0.9706552981572865" EFFECT_SIZE="1.1149228130360205" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="53" LOG_CI_END="0.10742457436056735" LOG_CI_START="-0.012934970592884414" LOG_EFFECT_SIZE="0.04724480188384145" MODIFIED="2010-12-19 23:29:16 +0000" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.07069979249501383" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="0.004998460658838015" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.044029834288077" CI_END="4.294666527723975" CI_START="0.2298713001798362" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9935897435897436" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="51.07703502046515" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="0.6329294473775307" LOG_CI_START="-0.6385152477458708" LOG_EFFECT_SIZE="-0.0027929001841701024" METHOD="MH" MODIFIED="2011-06-10 00:12:02 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.1528048031773761" P_Q="1.0" P_Z="0.9931297787702481" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="126" TOTAL_2="125" WEIGHT="100.0" Z="0.008610651795369522">
<NAME>Apgar score &lt; 7 at 5 minutes</NAME>
<GROUP_LABEL_1>Tight control</GROUP_LABEL_1>
<GROUP_LABEL_2>Very tight control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tight control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours very tight control</GRAPH_LABEL_2>
<DICH_DATA CI_END="28.031112609677777" CI_START="0.32107180779163014" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4476403360997032" LOG_CI_START="-0.49339782666037824" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2011-03-30 16:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.140175425099138" STUDY_ID="STD-El-Guindy-2008" TOTAL_1="60" TOTAL_2="60" VAR="1.3" WEIGHT="28.418803418803417"/>
<DICH_DATA CI_END="4.026113290667913" CI_START="0.009640782068838028" EFFECT_SIZE="0.19701492537313434" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6048859913225512" LOG_CI_START="-2.0158877343125043" LOG_EFFECT_SIZE="-0.7055008714949765" MODIFIED="2011-03-30 16:21:36 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="1.5394554594771999" STUDY_ID="STD-Magee-2007" TOTAL_1="66" TOTAL_2="65" VAR="2.3699231117141566" WEIGHT="71.58119658119658"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-04-15 13:42:04 +0100" MODIFIED_BY="Lynn Hampson">
<APPENDIX ID="APP-01" MODIFIED="2011-04-15 13:42:04 +0100" MODIFIED_BY="Lynn Hampson" NO="1">
<TITLE MODIFIED="2009-03-12 11:53:07 +0000" MODIFIED_BY="[Empty name]">Search strategies for CENTRAL, MEDLINE and mRCT</TITLE>
<APPENDIX_BODY MODIFIED="2011-04-15 13:42:04 +0100" MODIFIED_BY="Lynn Hampson">
<P>
<B>CENTRAL (<I>The Cochrane Library</I>)</B>
<BR/>#1 hypertens* near pregnan*<BR/>#2 gestational near hypertens*<BR/>#3 control or maintain or maintenance<BR/>#4 #1 or #2<BR/>#5 #4 and #3</P>
<P>
<B>MEDLINE</B>
<BR/>1.randomized controlled trial.pt.<BR/>2.randomized controlled trials/<BR/>3.controlled clinical trial.pt.<BR/>4.random allocation/<BR/>5.double blind method/<BR/>6.single-blind method/<BR/>7.or/1-6<BR/>8.clinical trial.pt.<BR/>9.exp clinical trials/<BR/>10.(clin$ adj25 trial$).tw.<BR/>11.((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>12.placebos/<BR/>13.placebo$.tw.<BR/>14.random$.tw.<BR/>15.research design/<BR/>16.or/8-15<BR/>17.comparative study/<BR/>18.exp evaluation studies/<BR/>19.follow up studies/<BR/>20.prospective studies/<BR/>21.(control$ or prospectiv$ or volunteer$).tw.<BR/>22.or/17-21<BR/>23.animal/ not (human/ and animal/)<BR/>24.7 or 16 or 22<BR/>25.24 not 23<BR/>26. pregnan$ adj2 hypertens$<BR/>27. gestational adj2 hypretens$<BR/>28. (control or maintain or maintenance).tw.<BR/>29. 26 or 27<BR/>30. 29 and 28 and 25</P>
<P>
<B>The metaRegister of Controlled Trials</B> (<A HREF="http://www.controlled-trials.com/mrct/">mRCT</A>), both active and archived registers:</P>
<P>hypertens% AND pregnan%.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>